Valuation dashboard for Editas Medicine, Inc. (EDIT) with P/E N/A, P/B 2.88, EV/EBITDA -4.25 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia.
Analysis Summary
Editas Medicine, Inc. reported revenue of $40.5M in the most recent fiscal year, growing at a 5-year CAGR of -14.9%.
Trailing-twelve-month margins: gross margin 56.9%, operating margin -174.7%, net margin -157.3%.
At the current price of $2.71, EDIT has negative trailing earnings (P/E not meaningful) and an ROE of -196.63%. Market capitalisation stands at $416M.
Balance sheet quality for EDIT: current ratio of 3.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.88 |
| EV / EBITDA | -4.25 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-5.10 |
| vs Current Price | -288.3% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| EDIT | Editas Medicine, Inc. | $416M | 2.88 | -196.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.71 |
| Market Cap | $416M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -196.63% |
| Return on Invested Capital | -46.81% |
| Return on Assets | -31.15% |
| Gross Margin | 56.90% |
| Operating Margin | -174.71% |
| Net Margin | -157.32% |
Related companies: ALLO · AVIR · CABA · CAPR · IMMP · KYTX · LYEL
Explore sector: Healthcare · Biotechnology
More sections of EDIT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks